TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23329236
Drug: Cisplatin/docetaxel (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/docetaxel (cisplatin 75 mg/m² and docetaxel 75 mg/m² every 3 weeks)
Study: 23329236
Drug: Oxaliplatin/docetaxel (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin/docetaxel (oxaliplatin 85 mg/m² and docetaxel 50 mg/m² every 2 weeks)
Study: 11016399
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (59 mg Al/ml), 10 ml three times daily for 6 weeks
Study: 9184389
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity oral anticoagulant treatment (target INR = 3)
Study: 9184389
Drug: Moderate-high intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-high intensity oral anticoagulant treatment (target INR = 4)
Study: 7033947
Drug: bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bendrofluazide 5 mg
Study: 7033947
Drug: indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indapamide 2.5 mg
Study: 30293931
Drug: Oral zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral zonisamide (4-25 mg/kg/day)
Study: 30293931
Drug: Intramuscular adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular adrenocorticotropic hormone (30-60 IU)
Study: 28130990
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment with different drug counseling models
Study: 23669386
Drug: 20, 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20, 100, or 200 mg of oral oseltamivir BID for 5 days
Study: 23669386
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oseltamivir once daily for 5 days
Study: 23669386
Drug: 75 or
Normalized name: Stalevo 75 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 or 150 mg of oral oseltamivir BID for 5 days
Study: 18985374
Drug: Prednisolone (PRED,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (PRED, 60 mg/day for 1 week)
Study: 17891560
Drug: ULEM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULEM therapy and conventional physical therapy (PT)
Study: 16898618
Drug: Alosetron (5-HT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (5-HT3 receptor antagonist)
Study: 16898618
Drug: Cilansetron (5-HT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilansetron (5-HT3 antagonist)
Study: 25158932
Drug: Drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatments
Study: 10052839
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g, single dose)
Study: 7595029
Drug: HBOC‐201 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 (up to 45 gm or 350 ml)
Study: 2099071
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (3 tablets, 300,000 binding units of the toxoid and 10,000 units of O‐antigens)
Study: 2099071
Drug: Parenteral vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vaccines
Study: 31594037
Drug: upadacitinib (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Study: 24135599
Drug: Colistine sulfate
Normalized name: Colistin Sulfate
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistine sulfate at 10 mg/kg of feed
Study: 21711517
Drug: PS-DHA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-DHA (300 mg PS/day) for 15 weeks
Study: 21711517
Drug: PS-DHA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-DHA (100 mg PS/day) for 30 weeks (open-label extension)
Study: 16608782
Drug: Intravenous prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prophylaxis alone
Study: 12876389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1p and 19q loss
Study: 10966240
Drug: E5531 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5531 (any dose)
Study: 8999618
Drug: Salbutamol 400
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 400 micrograms four times daily
Study: 26827294
Drug: Intranasal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal delivery of oxytocin (OT)
Study: 23139608
Drug: Symbiotic sachet
Normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symbiotic sachet Flortec(©) (Lactobacillus paracasei B21060) once daily plus high-fibre diet for 6 mo
Study: 11800416
Drug: Quinapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10-20 mg per day)
Study: 9389973
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) treatment for 12 months
Study: 2883987
Drug: epanolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol (200 mg)
Study: 31941544
Drug: Disease activity‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity‐guided treat‐to‐target strategy with tapering attempt
Study: 31941544
Drug: Disease activity‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity‐guided treat‐to‐target strategy without tapering attempt
Study: 26706911
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (6 to 8 sessions)
Study: 19711099
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day in 6-week cycles (Schedule 4/2)
Study: 30920122
Drug: Sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 800 mg/day
Study: 18791486
Drug: Raloxifene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene plus ossein-hydroxyapatite compound (RLX + OHC)
Study: 18791486
Drug: Raloxifene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene plus calcium carbonate (RLX + CC)
Study: 16773412
Drug: Urinary NGAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary NGAL levels <200 ng/ml
Study: 16773412
Drug: Urinary NGAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary NGAL levels >=200 ng/ml
Study: 14672296
Drug: Energy supplement
Normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supplement
Study: 8583618
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol daily
Study: 8583618
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg allopurinol daily
Study: 1957753
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg, alternate day)
Study: 7083769
Drug: Propranolol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (oral and intravenous)
Study: 7083769
Drug: Propranolol absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol absorption in untreated coeliac patients
Study: 7083769
Drug: Propranolol absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol absorption overall
Study: 26332193
Drug: Heparin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone, Bivalirudin alone, Heparin plus GPI, Bivalirudin plus GPI
Study: 26332193
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment phase
Study: 25179366
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) including thrombolysis with alteplase or urokinase, mechanical treatment, or both.
Study: 25179366
Drug: No intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intra-arterial treatment (no IAT).
Study: 15339411
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule
Study: 20473736
Drug: Polyene phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine capsule
Study: 16011059
Drug: Postoperative loco-regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative loco-regional radiation therapy
Study: 7593899
Drug: morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine plus midazolam (M)
Study: 2405741
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at a dose of 30 ng.kg‐1.min‐1 for 7 days
Study: 6994764
Drug: Guanfacine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (0.01 mg/kg)
Study: 6994764
Drug: Guanfacine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (0.02 mg/kg)
Study: 6994764
Drug: Guanfacine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (0.04 mg/kg)
Study: 6994764
Drug: Guanfacine (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (0.01, 0.02, 0.04 mg/kg)
Study: 2253662
Drug: Ibopamine 400
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 400 mg
Study: 25946916
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure intervention (5 sessions, 3 times a day for 2 weeks)
Study: 23932793
Drug: Pill-placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-placebo
Study: 11831541
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg daily for 4 days)
Study: 11831541
Drug: Rectal bromazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal bromazepam (3 mg)
Study: 10348276
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine (131I) ablation doses ranging from less than 30 mCi to 100 mCi.
Study: 8665549
Drug: Ketamine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (mean dose, 58 mg)
Study: 8665549
Drug: Alfentanil (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (mean dose, 11 mg)
Study: 2341121
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg intravenously)
Study: 2341121
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (5 mg intravenously)
Study: 31571633
Drug: RISUG (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RISUG (120 μl as bilateral vas intraluminal injection)
Study: 18277222
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy skills training group (16 sessions, once-weekly)
Study: 17135639
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus cyclophosphamide (TC) (75 and 600 mg/m2, respectively; n = 506)
Study: 17135639
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus cyclophosphamide (AC) (60 and 600 mg/m2, respectively; n = 510)
Study: 8513849
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Study: 3644367
Drug: Choice condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice condition (selected from three equally effective preparations)
Study: 24843529
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg
Study: 21961484
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg orally (positive control)
Study: 21961484
Drug: Plasma insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma insulin
Study: 12699262
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic oral contraceptive continuously
Study: 12699262
Drug: Progestins (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestins (oral, intramuscular, or IUD)
Study: 12699262
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist with immediate add-back therapy
Study: 12699262
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy postoperatively
Study: 8613630
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide nasal spray (110 micro g in each nostril once daily)
Study: 8613630
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide nasal spray
Study: 8613630
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg once daily)
Study: 1358234
Drug: Balsalazide 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 4 g/day
Study: 1358234
Drug: Balsalazide 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 2 g/day
Study: 3965343
Drug: Golytely lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely lavage (3‐4 L)
Study: 3965343
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (48‐h clear liquid diet, 240 ml of magnesium citrate and 'X‐Prep' senna derivative)
Study: 22632574
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (Early-PN)
Study: 31375142
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (Late-PN)
Study: 29805085
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) using JCP droplets or HDM tablets
Study: 20463579
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate
Study: 20463579
Drug: Immediate-release oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oral morphine sulfate
Study: 20463579
Drug: Global Medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Global Medication Performance Scale
Study: 18595975
Drug: Oral corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroid bursts (0, 1 to 4, and >=5 courses)
Study: 18595975
Drug: Cumulative inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative inhaled corticosteroid use
Study: 10510577
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection with concentrated PHKCV
Study: 10510577
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection with concentrated PHKCV after boosting
Study: 10510577
Drug: Five routine
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five routine doses of rabies vaccine
Study: 10510577
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) two or three doses after i.d. 0.1 mL nonconcentrated PHKCV
Study: 1436604
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of UDCA‐hemisuccinate orally twice a day for six months
Study: 1436604
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of S‐adenosyl‐methionine (SAMe) twice a day for six months
Study: 3548109
Drug: Conventional pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pancreatic enzyme preparation (Pankreon 700; 3 X 3 dragees daily) with cimetidine (300 mg)
Study: 3548109
Drug: New pH-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pH-sensitive enzyme preparation (Kreon; 3 X 6 capsules daily) comprising acid-protected granules
Study: 3548109
Drug: Conventional pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pancreatic enzyme preparation (Pankreon 700; 3 X 3 dragees daily) without cimetidine
Study: 31384878
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) group - 2.5 × 10^9 CFU
Study: 31384878
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) group - 1 × 10^10 CFU
Study: 23740093
Drug: Dysfunction markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysfunction markers (comorbidity, medication consumption, doctor's visits, difficulties in activities of daily living)
Study: 23330127
Drug: Carnosine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine added to treatment protocol for chronic brain ischemia
Study: 2967781
Drug: Tizanidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (4 mg three times daily) plus ibuprofen (400 mg three times daily)
Study: 2967781
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ibuprofen (400 mg three times daily)
Study: 28177710
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of bioactive collagen peptides (BCP) per day for 12 weeks
Study: 21906250
Drug: Implantable hemodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable hemodynamic monitoring (IHM) system used in treatment group
Study: 11153617
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg iv bolus over 15 mins and continuous infusion of 12.5 mg/kg/hr over 90 mins (n = 30)
Study: 25393622
Drug: Tacrolimus/MMF/steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus/MMF/steroids
Study: 25393622
Drug: Tacrolimus/MMF/steroids +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus/MMF/steroids + Rituximab
Study: 20432107
Drug: National Youth
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National Youth Anti‐Drug Media Campaign (NYADMC) awareness
Study: 18953854
Drug: Metoprolol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (oral or intravenous) administered from 2 hours before surgery to 30 days after surgery, dosage adjusted according to blood pressure and heart rate.
Study: 17273608
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of spray fenoterol (n = 41)
Study: 12966259
Drug: Combination AMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination AMI 1%/KET 0.5%
Study: 12966259
Drug: Combination cream
Normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cream (open-label phase)
Study: 10100330
Drug: Intervention course
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention course (behavior change skills taught in weekly lectures and peer-led labs)
Study: 8875970
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering interventions (low-fat/low-cholesterol diet, partial ileal bypass surgery, pharmacologic agents such as bile resins, fibrates, niacin, and HMG-CoA reductase inhibitors)
Study: 1395119
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg)
Study: 14510041
Drug: High-structure, behaviorally
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-structure, behaviorally oriented (HSB) treatment
Study: 14510041
Drug: Low-structure, facilitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-structure, facilitative (LSF) treatment
Study: 11098028
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (group B)
Study: 11098028
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after second cycle
Study: 8884859
Drug: Aprotinin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (group A, n = 46) - 2 x 10(5) KIU before incision, 2 x 10(6) KIU in priming solution, 5 x 10(5) KIU/h during CPB
Study: 1411667
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg controlled-release salbutamol (CRS)
Study: 1411667
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg controlled-release salbutamol (CRS)
Study: 2865721
Drug: Propofol for
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for induction and maintenance of anaesthesia, 9.0 mg/kg/h for 30 min followed by 4.5 mg/kg/h supplemented with fentanyl
Study: 28452866
Drug: Dopamine reuptake
Normalized name: Dopamine reuptake inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine reuptake inhibitor (methylphenidate)
Study: 28452866
Drug: Norepinephrine reuptake
Normalized name: Norepinephrine reuptake inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine reuptake inhibitor (reboxetine)
Study: 23907995
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg eteplirsen
Study: 23907995
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg eteplirsen
Study: 19219630
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further local treatment)
Study: 14628428
Drug: 5FU/Lev (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU/Lev (50 mg orally three times/day for 3 days, repeated every 2 weeks for 1 year)
Study: 14628428
Drug: 5FU alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU alone (450 mg/m2 i.v. bolus daily for 5 days and then weekly for 48 weeks)